# Surrogate markers of metabolic syndrome (MetS) and insulin resistance (IR) in children and young adults with type 1 diabetes: A systematic review & meta-analysis

## (MetS and IR in T1DM)

Authors: Sukeshini Khandagale<sup>1</sup>, Vinesh Kamble<sup>1</sup>, Chirantap Oza<sup>2</sup>, Shital Bhor<sup>2</sup>, Anuradha Khadilkar<sup>2</sup>#, Satyajeet Khare<sup>1</sup>#

- 1. Symbiosis School of Biological Sciences, Symbiosis International University, Pune 412115
- 2. Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune 411001

**Keywords:** Biomarkers, insulin resistance, metabolic syndrome, type 1 diabetes, children

## Research highlight:

- 1. The systematic review identified 30 research articles on the markers of MetS and IR in children with T1DM
- 2. Markers of glycaemic control did not associate with MetS in children with T1DM
- 3. Low Density Lipoprotein (LDL) levels showed a strong effect on MetS in children with T1DM suggesting it's application as a parameter for the diagnosis of MetS.

Systematic review and meta-analysis of metabolic syndrome and insulin resistance								
markers in T1DM children and young adults								
Methodology	Study Designs	Outcome						
Literature search WOS (n=86)	Case-Control = 12 Cohort based = 18	No significant difference in insulin dosage and HbA1c between T1DM with and without MetS suggests that manifestation of						
	Type of markers	MetS independent of glycaemic control in children with T1DM						
SCOPUS (n=739) PubMed (n=66)	Novel markers = 6 Routinely used markers = 24	LDL, which is not part of the diagnosis may be a useful tool for						
Studies included	Comparative studies	the assessment of MetS in children with T1DM						
(n=30)	MetS vs Non-MetS = 4 IR vs Non-IR = 2							
No. 100 Maria Control of the Control								

Note: WOS=Web of Science, T1DM=Type 1 Diabetes, MetS=Metabolic syndrome, IR=Insulin Resistance, HDL=high density lipoproteins, LDL=low density lipoproteins

## **Abstract:**

**Introduction:** Metabolic syndrome (MetS), a collection of risk factors for cardiovascular disease, and Insulin resistance (IR) are associated with diabetes. The diagnosis of both these conditions are based on specific clinical parameters. However, the efficacy of these parameters has not been systematically studied in paediatric population with T1DM.

**Methodology**: We performed a systematic review and meta-analysis in paediatric populations of type 1 diabetes. We assessed the strength of association of the parameters of MetS and IR. The meta-analysis was performed using 'metaphor' package in R. A random effect model was used to study the strength of association by estimating Hedge's g.

**Results**: The systematic review resulted in identification of 30 studies on MetS and IR in paediatric patients with T1DM. Insulin dosage and HbA1C, markers for glycaemic condition showed no association with MetS in patients with T1DM. In the lipid profile, increased triglyceride (TG) and low-density lipoprotein (LDL) showed better effect size than reduced high-density lipoprotein (HDL). In case of insulin resistance, heterogeneous nature of studies made it difficult to carry out a meta-analysis. A descriptive review of existing and novel markers is thus provided.

**Conclusion**: Lack of association between markers of glycaemic condition suggested that MetS may develop independently of glycaemic control in children with T1DM. Other than TG and HDL, LDL may be used in the diagnosis of MetS. From the descriptive analysis it could be observed that a standard protocol for the diagnosis of IR is needed.

#### **Introduction:**

Type 1 diabetes mellitus (T1DM) is an autoimmune disorder in which the pancreatic beta cells are destroyed by the host immune system. The patient, as a result, is treated with exogenous insulin. The peak age for T1DM diagnosis is 5-9yrs and 10-14yrs<sup>1,2</sup>. The prevalence of T1DM is rising among the young population<sup>3-6</sup>. Patient with recently diagnosed T1DM generally have a lower body mass index; however, prevalence of obesity has increased among these patients during the recent decades<sup>7</sup>. Obesity is associated with insulin resistance and metabolic syndrome which are the risk factors for cardiovascular diseases. Therefore, diagnosis and management of metabolic syndrome (MetS) and insulin resistance (IR) are crucial for the prevention of cardiometabolic risks.

The prevalence of MetS in T1DM is suggested to be 23.7% and is increasing<sup>8,9</sup>. The diagnosis of MetS is based on three different criteria that are laid down by the World health Organization (WHO), the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III), and the International Diabetes Federation (IDF)<sup>10</sup>. These criteria are based on anthropometric measurements such as waist circumference (WC), hypertension (HTN) and biochemical parameters such as the lipid profile (Table 1).

Table 1: Diagnostic criteria for metabolic syndrome according to different organization.

Criteria laid by	Components of MetS	Cut-offs for adults	
WHO (1998) <sup>11</sup>	Insulin resistance (by impaired	FG>100mg/dl, IGT>140 mg/dl 120 minutes after	
	fasting glucose (FG) or impaired	ingestion of 75 grams of glucose, WHR: $\geq 0.90(M)$ ,	
	glucose tolerance (IGT) or	$0.85(F)$ or BMI $\geq$ 30kg/m2, TG $\geq$ 150mg/dl or HDL-	
	Hyperinsulinemic Euglycaemic	$C \leq 35 \text{mg/dl(M)},  39 \text{mg/dl(F)},  BP \geq 160/90 \text{mmHg},$	
	Clamp (HEC)) with (any 2 of the	Urinary albumin excretion of 20 µg/min or albumin-to-	
	following: obesity, dyslipidemia,	creatinine ratio of 30 mg/g	
	high systolic, high diastolic blood		
	pressure, increased urine		
	microalbumiuria)		
NCEP ATP III	Any 3 of five: Obesity,	Waist circumference: $\geq$ 40 inches (M), $\geq$ 35 inches (F),	
(2005 revised) <sup>10</sup>	Hyperglycemia, dyslipidemia,	Fasting glucose ≥100 mg/dl or Rx, TG≥150 mg/dl or	
	high systolic or high diastolic BP.	Rx, HDL cholesterol $\leq$ 40 mg/dl (M), $\leq$ 50 mg/dl (F); or	
		Rx, HTN <u>&gt;</u> 130 mmHg systolic or <u>&gt;</u> 85 diastolic or Rx.	
IDF(2007) <sup>12</sup>	Central obesity (by waist	Waist circumference: $\geq 94$ cm(M), $\geq 80$ cm(F),	
	circumference) with (2 of the four	$FG \ge 100 \text{mg/dl}, TG \ge 150 \text{mg/dl}, HDL \le 40 \text{mg/dl}(M),$	
	criteria: FG, TG, HDL, BP)	≤50mg/dl(F), BP≥130mmHg or ≥85mmHg diastolic or	
	*If BMI>30kg/m <sup>2</sup> central obesity	Rx	
	can be assumed		

**Note:** WHR (waist to hip ratio), HDL (High Density Lipoprotein), BP (Blood Pressure), BMI (Body Mass Index), Rx (on drugs of treatment for the condition)

Most of the cut-offs for the diagnosis of MetS are developed for the adult population <sup>13–15</sup>. These parameters are modified only by changing the threshold for use in paediatric population. In case of type 1 diabetes, these MetS parameters may not be stable due to exogenous insulin therapy and pubertal age of the paediatric patients.

Along with MetS, an increased prevalence of insulin resistance (IR) is also observed in patients with T1DM. Insulin resistance is generally a characteristic of T2DM and therefore, the development of insulin resistance in T1DM is termed as double diabetes <sup>16–20</sup>. Various factors such as food habits, reduced physical activity, gender, age, and genetic predisposition may have a role to play in the development of IR in T1DM <sup>21,22</sup>. IR has been associated with various other disorders such as polycystic ovary syndrome (PCOS)<sup>23,24</sup>, non-alcoholic fatty liver disease (NAFLD)<sup>25–27</sup> etc. The increased frequency of IR in T1DM makes children with T1DM more prone to the development of PCOS and NAFLD. Presence of IR in children with T1DM also increases the risk of development of various microvascular complications<sup>28</sup>. Hence, the diagnosis of IR may help clinicians to implement preventive measures or add an adjuvant treatment.

The diagnosis of IR in T2DM depends on measurement of fasting insulin levels which are negligible in T1DM. Therefore, the indices used for the diagnosis of IR in Type 2 diabetes have little use in T1DM. The gold standard method for the diagnosis of IR in children with T1DM is the Hyperinsulinemia Euglycemic Clamp (HEC) in which the glucose concentration is maintained by variable infusion of exogenous glucose and insulin<sup>29</sup>. However, the HEC technique is expensive, and space and time consuming. Therefore, various alternate methods have been developed for the diagnosis of IR that rely on indirect markers such as estimated glucose disposal rate (eGDR)<sup>30</sup>–<sup>33</sup>, Insulin Sensitivity Score (ISS)<sup>34</sup> and, insulin sensitivity equation (eIS)<sup>35</sup>. The indices for the diagnosis of IR in

T1DM are provided by Epidemiology of Diabetes Complications (EDC), Search for diabetes in youth (SEARCH), and Coronary Artery Calcification in T1DM (CACTI) (Table 2).

Table 2: Indices provided for calculation of insulin resistance in Type 1 diabetes.

Groups	Equations	Target population	Threshold for IR
IDF (2007) <sup>36</sup>	$eGDR = 24.31-12.22 \times (WHR)$	Adult T1DM (compared	Does not provide cut-
	3.29×(Hypertention)-	with HEC)	offs, usually studied by
	0.57×(A1C[%])		dividing groups in tertiles
			or quartiles <sup>37</sup> .
SEARCH	IS scores = $Exp(4.64725-$	Adolescence with	Does not have provide
$(2011)^{34,38}$	0.02032(waist[cm])-	T1DM, T2DM and non-	cut-offs
	0.09779(HbA1c[%])-	diabetic (compared with	
	0.00235(TG[mg/dlL]))	HEC)	
CACTI (2011) <sup>39</sup>	eIS = Exp(4.1075-	Adult T1DM (compared	Does not provide cut-
	0.01299×(waist[cm])-	with HEC)	offs, parameters are
	1.05819×(insulin dose)-		tested as models with and
	$0.00354 \times (TG[mg/dL)$ -		without adiponectin and
	0.00802×(DBP[mmHg]))		fasting/non-fasting state

**Note:** EDC (Epidemiology of Diabetes Complications), SEARCH (SEARCH for Diabetes in Youth), CACTI (Coronary Artery Calcification in T1DM), eGDR (estimated glucose disposal rate), IS (insulin sensitivity score), eIS (estimated insulin sensitivity, WHR (waist to hip ratio), TG(Triglycerides), DBP (Diastolic Blood Pressure).

The indices for IR in T1DM have been validated by direct comparison with HEC<sup>34,38,40,39</sup>. There are no threshold or cut-offs provided for these indices. However, many authors have provided cohort based thresholds. Most of these studies include adults with T1DM. The study by Oza et al has provided cut-offs for all three indices in children with T1DM (Supplementary Table 1). The exogenous insulin administration and pubertal age may interfere with the existing parameters of MetS and IR. Therefore, a systematic review and meta-analysis is needed for both these conditions.

In this systematic review we have attempted to summarize and compare various individual indirect markers for the diagnosis of MetS and IR in T1DM for their efficacy. Our analysis suggests that metabolic syndrome may develop independently irrespective of glycaemic control in children with T1DM. In lipid profile, LDL and Triglycerides were found to exert a strong effect on metabolic syndrome whereas HDL exerted a moderate effect. Lack of consistency in study designs for the detection of insulin resistance in T1DM made it difficult to compare the effect size of markers of IR. Therefore, we provide a descriptive review of the existing and novel markers for IR in T1DM.

## Methodology:

This is an exploratory meta-analysis and follows the PRISMA (Preferred Reporting of Systematic Review and Meta-analysis) guidelines.

## Search strategy, and Inclusion and exclusion criteria:

Two authors (SK and VK) independently searched for the relevant keywords in three databases (PubMed, SCOPUS, Web of Science) for identification of research articles related to metabolic syndrome and insulin resistance in children, adolescents, and young adults with T1DM. The search was performed till May 5, 2023. The articles were from 1982 to 2023. The search for the relevant keywords was as follows

((("Type 1 Diabetes" OR "IDDM" OR "insulin dependent diabetes" OR "T1DM") AND ("insulin resistance" OR "IR" OR "Metabolic syndrome" OR "MetS" OR "insulin sensitivity" OR "IS")) AND ("Molecular markers" OR "markers" OR "Biological markers" OR "Clinical markers" OR "gene expression markers")) AND ("Paediatric" OR "child" OR "children" OR "adolescent" OR "adolescence" OR "young adult").

The search was limited to peer reviewed English articles. Only original research articles were included for this review. Studies that had a type 1 diabetes population with the age group <25yrs were retained. The studies were then imported to a Rayyan software for screening and removal of duplicates<sup>41</sup>. Studies using animal models, cell lines, and organ tissue samples were excluded. Studies including patients with complications of diabetes and on treatment other than insulin therapy were excluded.

#### Selection of studies and data extraction:

We segregated the studies based on presence or absence of metabolic syndrome and insulin resistance in the T1DM population. The studies that provide markers for such conditions, either standard (insulin dose, eGDR for IR, IDF criteria for MetS) or surrogate (BMI, WC etc.), were included in this review. Meta-analysis was performed only if multiple studies with similar parameters were available. Other studies were utilized for descriptive review. Parameters such as duration of diabetes, insulin dosage, HbA1c, and lipid profile were assessed in each study. The sample size, mean, and standard deviation (sd) for each parameter were recorded accordingly. If median and interquartile range were provided they were converted to estimated mean and variance depending on sample size 42. Author names, publication year, ethnicity, and gender details of the population were also recorded for the studies that were part of the systematic review (Table 3).

## Statistical analysis and evaluation:

Meta-analysis was performed when two or more studies reported mean, standard deviation, and sample size. Metaphor package was applied for the analysis<sup>43</sup>. Standard Mean Difference (SMD) was calculated using R (version 4.1.1). We calculated the effect size (ES) in terms of hedges g that corrects for the sample size providing unbiased adjusted ES. Random effects model (REM) was used for quantitative meta-analysis. A forest plot was used to visualize summary of results<sup>44</sup>. Chi-squared test was used to measure heterogeneity (p val<0.1). The I<sup>2</sup> statistic was used to estimate if the heterogeneity was considerable (I<sup>2</sup>>40%)<sup>45</sup>. The strength of relationship between parameters and traits was estimated based on the effect size (0-0.2: no effect; 0.2-0.5: small; 0.5-0.8: moderate; 0.8-1: large; >1: very large effect)<sup>46</sup>.

## Assessment of Sensitivity and publication bias:

Funnel plots<sup>47</sup> were used for visualization of publication bias. The pooled results were analysed for their sensitivity by sequential removal of individual studies and their effect on heterogeneity.

#### **Results:**

## Identification of studies for diagnostic markers of metabolic syndrome and insulin resistance

We identified 67 research articles on PubMed, 930 on SCOPUS, and 88 on Web of Science by searching keywords in titles and abstracts. After applying the filters for language and exclusion criteria, 66, 739, and 86 articles were retained. Manual search provided 3 additional studies. These articles were then imported in Rayyan<sup>41</sup>. In this software 78 duplicate articles were removed and 816 unique original research articles were retained. Based on the screening of abstracts and titles, 743 articles were omitted. Full text scrutiny was performed on 73 research articles, and 30 research articles were retained based on inclusion and exclusion criteria (Figure 1).

The general nature of these research articles is mentioned in Table 3. All were observational studies with a cross-sectional or longitudinal design. The data in the studies was either prospectively collected or used retrospectively from registries and hospitals.




Figure I: PRISMA flow diagram for the illustration of the identification and screening process. Search terms were used to compile the results in different databases and imported together in software Rayyan for duplicates removal and screening

## Qualitative summary and characteristics of studies:

As mentioned earlier, we limited our search to observational studies. There were a total of 30 studies with standard and surrogate markers of metabolic syndrome and IR in T1DM. 12 studies were based on case-control and 18 studies were cohort based. Six studies provided novel markers for IR whereas, 24 studies used existing parameters for IR and MetS. Information about ethnicity was not available for 15 studies (Table 3). Five of the 30 studies compared T1DM patients with healthy controls whereas, another 5 studies compared T1DM with T2DM patients. Four studies assessed MetS in T1DM by grouping them according to IDF criteria. The grouping of studies for IR was difficult as only two studies have classified the T1DM population on the basis of IR indices (eGDR)<sup>48,49</sup>.

Table 3: Characteristic of studies included in the systematic review

	•	Type of Study	ethnicity	Case (M/F)- Control (M/F) or Cohort(M/F)	_	Markers for MetS/ IR	Age
1	Nadeau et al. 2010 <sup>50</sup>	С,Р	Black (8.3%), Hispanic (8.3%), White(75%), other(8.3%)			HEC with VO2 peak (r=0.61, p=0.007)	12-19yrs
	D. Dabelea et al 2011 <sup>34</sup>	C,P	Non-hispanic whites, Hispanics, African American)	Case (26/43) Control (8/17)		HEC with IS score (SEARCH) (r=0.65, p=0.0001)	12-19yrs
	D. Dabelea et al. 2011 <sup>48</sup> *	C,P				IS score by SEARCH (IR<8.15)	<20yrs
4	Davis et al. 2012 <sup>51</sup>	C,P	NA	Case (18/12), Control (8/6)		Higher insulin dose, high HbA1c	0-18yrs
	Rathsman et al. 2012 <sup>52</sup>	С,Р	Caucasian	Case (12/8), Control(7/13)	НС	MetS by NCEP ATP III, WHO, IDF. HEC(Si) to cIMT: r=0.22	14-20yrs
	Narges Safai et al., 2015 <sup>53</sup>		18 immigrants, 12 unreported ethnicity, others Danish origin	Control (266/231)		Adiponectin, leptin (increase in both increases insulin sensitivity)	0-15yrs
7	Chan et al. 2017 <sup>54</sup>	C,P	NA	Case (46/54), Control (11/31)		HEC with AST & cholesterol (r=-0.21, p<0.05), BMI% (r=-0.40, p<0.001), TG(r=-0.34, p<0.001), WC(r=-0.45, p<0.001)	12-19yrs
	Cree-Green et al. 2018 <sup>55</sup>	С,Р	T1DM are more caucasian	Case (16/19), Control(6/16)		HEC with FFA (r=-0.46, p=0.005), Leptin (r=-0.44, p=0.008)	14-17yrs
	E Gourgari 2020 <sup>56</sup> *	L,P	Non-Hispanic White 72%, other 28%	Case(196/180), Control(55/102)		IS score by SEARCH (ISS>8.15 included for T1DM)	•

	name/year	Type of Study	ethnicity	Case (M/F)- Control (M/F) or Cohort(M/F)	_	Markers for MetS/ IR	Age
10	Hamed et al. 2021 <sup>57</sup>	L,P	NA	Case (3/4), Control(22/37)		Acanthosis nigricans, family history of DM, c-peptide, HbA1c	9-12yrs
11	Calcaterra et al. 2021 <sup>58</sup>	C,P	NA	Case (0/14), Control (0/18), Control (0/20)	НС	eGDR=21.158 + (-0.09 * waist circumference) + (-3.407 * HTN) + (-0.551 * HbA1c) eGDR<8.77mg kg <sup>-1</sup> min <sup>-1</sup> low adiponectin and high Kisspeptin in IR	
12	Monika Grabia et al. 2021 <sup>9</sup>	C,P	Polish		MetS	MetS by IDF, NCEP ATP III, WHO, eGDR by 21.158 – (0.090 × WC) – (3.407 × HT) – (0.551 × HbA1c) ≤8 mg/kg/min (for MetS diagnosis)	
13	Stone et al. 2006 <sup>59</sup>	L,R	NA	Cohort(161)		Higher BMI, higher insulin dose, DHEAS	13.7 <u>+</u> 2.2yrs
14	Szadkowska et al. 2008 <sup>51</sup>	C,P	NA		Lipid parameters and adiposity markers	HEC (M <sub>lbm</sub> ) with lipid [Cholesterol (r=-0.18, p=0.012), HDL (r=0.15, p=0.035), LDL (r=-0.32, p=0.002), TG (r=-0.32, p<0.001)],  SBP(r=-0.15, p=0.029), Adiposity [BMI(r=-0.29, p<0.001), WC(r=-0.35, p<0.001), Tricep (r=-0.16, p=0.027), Subscapular (r=-0.22, p=0.002), Body fat(r=-0.19, p=0.006)]	>8 - <18yrs
15	Mazumder et al. 2009 <sup>52</sup>	·	Asian	Cohort (30/28)		Increased insulin dose, acanthosis nigricans, increased body fat	16.5 <u>+</u> 2.3
16	Girgis, Scalley, and park 2012 <sup>57</sup>	C,P	NA	Cohort (29/32)		eGDR= 24.31- (12.2*WHR)- 3.29*hypertension- 0.57*HbA1c. obese vs non-obese T1DM (eGDR 6.5±1.6 8.6±1.8 mg/ kg min	16-25yrs

	name/year	Type of Study	ethnicity	Case (M/F)- Control (M/F) or Cohort(M/F)	_	Markers for MetS/ IR	Age
						respectively, p = 0.29) no cut-offs	
17	Giuliana Valerio 2012	C,P	Caucasian of Italian origin	` ,	MetS vs No- MetS	IDF for MetS, logistic regression: [insulin dose (OR=1.04, 95% CI 1-1.07,p=0.025),WHR (OR=11.03, 95% CI 5.23-23.24, p=<0.001)	
18	Maya jesic et al., 2013	С,Р	NA	Cohort (51/49)	micro	High insulin dose, hypercholesterolemia, DHEAS	11-19.4yrs
19	Lecaire and Palta 2015 <sup>60</sup>	L,P	White (97%)		Follow-up study	Insulin dose, Adiponectin	11.2(6.8)
20	Cedillo et al. 2015 <sup>61</sup>	C,P	NA	Cohort (155/108)	central obese vs non central obese	BMI>95 <sup>th</sup> percentile for obesity, WHtR>0.5 for central obesity (obesity driven IR)	
21	Siraz et al. 2017 <sup>62</sup>	C,P	NA	, ,		Fetuin A (AUC=0.672, 95% CI 0.558-0.773; p=0.022), higher ALT	
22	Bjornstad et al.2017 <sup>62</sup>	С,Р	NA	Cohort (20/21)	leptin tertiles	HEC, leptin tertiles related to VO2 peak independent of IS	12-21yrs
23	Sevaliev et al. 2019 <sup>63</sup>	C,R	84% Jewish, 16% Arab	Cohort (48/48)		Patient with high BMI showed component of MetS such as high SBP, low HDL compared to normal BMI patients.	
24	Soliman, Mosaad, and Ibrahim 2019 <sup>13</sup>	C,P	NA	, ,	MetS	IDF for MetS, eGDR correlates with Age(r=-0.27, p=0.001), duration of diabetes(r=- 0.18, p=0.02), weight(r=- 0.35, p<0.001), BMI(r=- 0.27, p=0.001), SBP(r=- 0.48, p<0.001), DBP(r=- 0.4, p<0.001), WC(r=- 0.5, p<0.001), HbA1c(r=- 0.69, p<0.001), LDL &	

	Author name/year	Type of Study	ethnicity	Case (M/F)- Control (M/F) or Cohort(M/F)	groups	Markers for MetS/ IR	Age
						TG (r=-0.18, p=0.02), cholesterol (r=-0.16, p=0.04)	
25	Marigliano et al. 2020 <sup>65</sup>	C,P	Caucasian	Cohort (8/7)	(but lean population)	eGDR with exogenous CHOs oxydized (r=0.7, p<0.02), differential enrichment of C12/C13 in the expired breath test (r=0.59, p<0.05).  ISS with exogenous CHOs oxydized(r=0.61, p<0.05), differential enrichment of C12/C13 in the expired breath test(r=0.62, p<0.05)	
26	Nishtala et al. 2020 <sup>49</sup>	C,R	Caucasian, African, Caribbean, South Asian, others			eGDR <sub>BMI</sub> tertiles correlated with clinical parameter. Low eGDR had high cholesterol and TG.	
27	Koken et al. 2020 <sup>14</sup>	L,P	NA		MetS	IDF, WHO, NCEP ATP III.  WC, TG significantly high (p<0.001) and LDL also high (p=0.05) in MetS positive.	·
28	Morandi et al. 2021 <sup>64</sup>	C,P	NA			CACTI(eIS) for IR.  D6D activity with eIS (r=-0.32, p=6.6x10 <sup>-5</sup> ), TG(r=0.24, p=0.003)	15.5-18.9yrs
29	Gomes et al. 2022 <sup>65</sup> *	С,Р	Caucasians 48%		non-	IDF for MetS for 10 to 16, and IDF adult for above 16yrs	10-19yrs
30	Shah et al. 2023 <sup>66</sup>	С,Р	Asian	Cohort(38/41)		Adiponectin to Leptin ratio as MetS marker	10-21yrs

<sup>\*=</sup>Multicentre study. All other are single centre studies.

(ISS-insulin sensitivity score, SI-insulin sensitivity, eGDR-estimated glucose disposal rate, GIR-glucose infusion rate, ALT-alanine amino transferase, eIS-estimated insulin sensitivity, ALR-Adiponectin to Leptin ratio)

**Assessment of markers for metabolic syndrome in T1DM**: Out of 30 studies only 4 studies have grouped T1DM children as patients being metabolic syndrome positive and metabolic syndrome negative (Table 4). The

C=cross-sectional, L= longitudinal, P=prospective, R=retrospective.

parameters such as units of insulin, HbA1c, waist circumference, and lipid profile were selected for our metaanalysis. Summary statistics for fasting glucose and hypertension were not available.

In our meta-analysis using Random Effect Model (REM), WC (d =1.34, [95% CI: 0.79-1.90]) and TG (d=0.85, [95% CI: 0.14-1.55]) showed significantly large effect size whereas, HbA1C (d=0.75, [95% CI: -0.20-1.71]), and LDL (d=0.73, [95% CI: 0.15-1.32]) showed a moderate effect on MetS. The effect size was significant for LDL but not for HbA1C. On the other hand, HDL (d=-0.37, [95% CI: -0.65- -0.10]) showed a significantly small negative effect. Units of insulin dose (d=0.17, [95% CI: -0.06-0.4]) also showed no significant effect on MetS (**Error! Reference source not found.**).

Table 4: Studies that have categorized children with T1DM based on presence or absence of metabolic syndrome and insulin resistance.

ana n	nd insulin resistance.						
no	Author	Sample number	Parameters in the study	Origin/other			
	A. Studies based on the presence or absence of metabolic syndrome						
1	Giuliana Valerio et al., 2012 <sup>67</sup>	411 (39/372)	Insulin dose(U/kg/day), WC (cm), BMI(kg/m <sup>2</sup> ), W/H ratio, HbA1c(%)	Caucasian of Italian origin, age 16-19yrs, >1yr of duration of diabetes			
2	M Soliman et al., 2021 <sup>57</sup>	160 (21/139)	Duration of diabetes(yr), insulin dose(U/kg/day), HbA1C, weight, height, BMI(%), SBP(mmHg), DBP(mmHg), WC(cm), TG(mmHg),	Afrocentric ethnicity, Age<18yrs, duration of diabetes 1yr or more,			
3	OY Koken et al., 2020 <sup>14</sup>	200 (21/179)	Duration of diabetes(yr), family history, insulin dose, Acanthosis, WC(cm), HbA1c(%), TG(mg/dl), HDL(mg/dl), LDL(mg/dl)	Turkish, age 13.8±2.8yrs, 4.6+3.3yrs of duration of diabetes			
4	Monika Grabia et al., 2022 <sup>68</sup>	60 (20/40)	WC(cm), W/H ratio, WHtR, BMI (kg/m²), HbA1C(%), eGDR(mg/kg/min), TC(mg/dl), LDL(mg/dl), HDL(mg/dl), TG(mg/dl), SBP(mmhg), DBP(mmhg)	Polish, Age 10-17yrs, 2-7yrs of diabetes			
	B. Studies ba	sed on the presence or	r absence of insulin resistance				
1	Nishtala R et al, 2020 <sup>49</sup>	175 (eGDR<7.34=58, eGDR 7.34- 8.92=56, eGDR>8.93=61))	Age, sex, ethnicity, duration of diabetes, BMI, HbA1c, eGDR, eGFR, SBP, DBP, TC, HDL, LDL, TG	Mixed(Caucasian 81.7%, African carribean2.3%, south Asian 6.3%, other 2.3%), Age 22±1.6, 1-23yrs of diabetes			
2	Dabelea et al., 2011 <sup>48</sup>	1694 (IS=1248, IR=446)	Onset age, duration of diabetes, family history, IS score, FCP, GADA titres, BMI as z score, WC	67.9% Non-Hispanic whites (NHWs), 13.3% Hispanics, 13.4% African Americans (AAs), 4.1% Asian/ Pacific Islanders (APIs), and 1.3% American Indians (AIs), Age <20yrs, duration of diabetes is mixed population.			

## Assessment of publication bias:

No heterogeneity was observed for units of insulin dosage and HDL. On the other hand, HbA1c, LDL, TG, and WC showed presence of heterogeneity in datasets (Figure II). Since, the markers showed a significant heterogeneity, we decided to assess the publication bias. A funnel plot analysis was performed for all the markers mentioned above (Supplementary Fig 1). HDL and the units of insulin did not show any outliers. The publication bias was assessed for the remaining parameters which were HbA1c, WC, TG, and LDL by sequential removal of each study. The study by Monika Grabia et al 2022 strongly contributed to the heterogeneity for HbA1C, TG, and HDL. Removal of this dataset removed the heterogeneity and improved the effect size of TG (from 0.85 to 1.18) and LDL (from 0.73 to 1). The effect size of HbA1c (from 0.17 to 0.32) on the other hand, reduced. In case of WC, strong heterogeneity was contributed by the study by Soliman et al 2019. Removal of this dataset improved

the effect size of waist circumference (from 1.34 to 1.63). The possible sources of heterogeneity are discussed later. In summary, the triglyceride, LDL, and waist circumference seem to have a significantly large effect on MetS (Supplementary fig 2).




Figure II: Comparison between parameters of metabolic positive and metabolic negative groups of type 1 diabetes patients. A: Insulin dosage units, B: HbA1c, C: Waist circumference, D: Triglyceride, E: High density lipoprotein, F: Low Density Lipoprotein

Assessment of markers for IR in T1DM: Out of the 30 studies, only two studies had grouped the participants based on presence or absence of IR<sup>48,49</sup>. In both these studies the measurement of IR was performed by using eGDR. However, Nisthala et al., 2020, divided the patients with T1DM by eGDR<sub>BMI</sub> and the association of eGDR<sub>BMI</sub> with different clinical parameters was observed. The study suggested that the population in lower quartiles of eGDR<sub>BMI</sub> had significantly higher levels of total cholesterol and triglycerides. Dabelea et al., 2011 attempted to segregate the population of children with T1DM and T2DM based on eGDR. The study found stronger association of IR in children with T2DM than in T1DM. The parameters to calculate eGDR and the study design were not consistent between these two studies (Table 4). Therefore, a meta-analysis could not be performed. As a result, we provide a descriptive review of other markers for IR. Some of the markers that include Volume of Oxygen uptake during peak exercise (VO2<sub>peak</sub>), Free Fatty Acid (FFA), Leptin, cIMT (carotid intima media thickness), have been validated using HEC. A few others markers have been validated using indices such as eGDR, SEARCH, and CACTI (Table 3).

Quantitative markers frequently used by clinicians include measurement of insulin dosage in combination with HbA1c<sup>51</sup>, central obesity<sup>59</sup>, and body fat<sup>38</sup>. Along with HbA1c, family history for T2DM is an important parameter. Central obesity measured by waist to height ratio (WHtR) >0.5 and BMI>95 percentile are also suggested parameters for IR<sup>61</sup>. Body fat estimated by thickness of triceps and subscapular skin fold have been

used to predict body fat<sup>38</sup>. A qualitative marker: acanthosis nigricans is also used as an indicator of IR; however, it is more related to obesity than insulin resistance<sup>48,57,58,69</sup>.

Some of the novel quantitative markers such as adiponectin, leptin, fetuin A, and kisspeptin are being investigated for the assessment of IR. A longitudinal study in T1DM children suggested that levels of adiponectin, (a hormone produced by adipocytes with a role in insulin sensitization) were strongly related to WC and insulin dose in 20yr old adults with T1DM<sup>60</sup>. Adiponectin and leptin (another hormone produced by adipose tissue involved in maintenance of normal body weight), both have been studied in association with IR<sup>53</sup>. It has recently been suggested that leptin may act as a potential biomarker for the detection of IR in T2DM. In case of T1DM, the association of leptin with IR is not very well studied. However, a few reports suggest that fluctuations in leptin levels are observed in children and adolescents with T1DM<sup>53,70</sup>. Increase in fetuin A, a hepatokine and an adipokine, is associated with insulin resistance and obesity. In T1DM, this association was limited to glycemic control and as a risk predictor for complications of diabetes. Further studies to assess the role of fetuin A in insulin resistance are needed. Another hormone, Kisspeptin (produced in the hypothalamus) inversely associates with adiponectin levels and in turn, to insulin sensitivity<sup>71</sup>. However, the association was only studied in reproductive age female population. Further studies will be required to conclude Kisspeptin as a marker for IR. Two studies have shown an association of insulin resistance markers (increased insulin dose, increased BMI and, increased Dehydroepiandrosterone sulphate (DHEAS)) with increased micro-albuminuria<sup>59,72</sup>. The DHEAS is a precursor for sex hormones and is known to act as an insulin sensitizer. VO2<sub>peak</sub> which is a measure of cardiovascular and skeletal muscle oxidative function shows a significant moderate positive correlation with HEC (reduced GDR by HEC indicate IR)<sup>50</sup>.

Other less studied novel indicators include carbohydrate (CHO) oxidation and Delta 6 desaturase (D6D) activity. The CHO oxidation which estimates the capacity to oxidise a meal in the form of differential 13C/12C enrichment in the expired air using flow isotope mass spectrometry, has been associated with IR. The CHO oxidation showed a moderate correlation with eGDR in T1DM<sup>73</sup>. A high activity of D6D, a rate limiting enzyme in production of long chain Poly Unsaturated Fatty Acids (PUFA) has been associated with decreased insulin sensitivity therefore, increased activity of D6D has been suggested to be a strong marker for IR in T1DM adolescents<sup>64</sup>. All the novel quantitative markers are still under investigation and are not part of routine clinical applications.

## **Discussion:**

Metabolic syndrome (MetS) and Insulin resistance (IR) in combination and independently can be the risk factors for cardiovascular diseases. Clinicians tend to use surrogate markers for the diagnosis of MetS and IR in children with T1DM. We performed a meta-analysis to investigate the effect size of these parameters for the diagnosis of MetS in paediatric T1DM patients. Inconsistency in measurement methods made it difficult to perform a similar meta-analysis for IR (Table 4).

Variations in glucose levels are expected to contribute majorly to complications in T1DM T1DM. Thus, fasting glucose is considered as a component for the diagnosis of MetS by WHO, NCEP III, and IDF (Table 1). However, mean fasting glucose levels are not provided in most studies. Waist circumference was strongly associated (with large effect size) with MetS in T1DM (Figure 1 C). In our meta-analysis, insulin dosage and HbA1c showed a poor effect size suggesting that the MetS appears independent of glycaemic condition in paediatric T1DM patients (Figure 2 A & B). Since, all four studies made use of the IDF criteria which require central obesity as a mandatory component for the assessment of MetS, this association was expected. However, this association was observed with a considerable heterogeneity. The heterogeneity was contributed by the study Soliman et al (2019). The study cohort was from Egypt and the population has been shown to have a different cut-off for waist circumference for obesity<sup>74</sup>. Removal of this study removed the heterogeneity and increased the effect size (Supplementary Fig 1 B). Our results fall in line with previous studies where waist circumference predicted metabolic syndrome in adults with T1DM<sup>75</sup> and was significantly associated with metabolic syndrome in children who did not have diabetic<sup>76</sup>.

Increased triglycerides and LDL were also associated (large and moderate effect size respectively) with metabolic syndrome in patients with T1DM (Figure1 D & F). This association too was observed with heterogeneity, the source of which was identified to be the study by Monika Grabia et al (2021). Grabia et al used median and interquartile range as summary statistics whereas, others have used mean and standard deviation<sup>42</sup>. Though, we attempted to convert the summary statistics to means, we feel that this may have contributed to the heterogeneity in the result. The omission of this study did not alter the effect size for TG whereas, effect size for LDL improved from moderate to large (Supplementary Fig 1D). TG are already a part of IDF criteria and together with WC provide a better diagnostic efficiency for MetS<sup>77</sup>. The LDL also showed a strong association with MetS.

Considering that LDL is not part of the IDF criteria for MetS this association is noteworthy. Increased LDL is suggested to be a marker for cardiovascular risk. It is well documented that increased LDL levels are associated with increased CVD mortality and CVD risk<sup>78</sup>. Significantly increased LDL was observed in children who do not have diabetes but had predisposition to MetS<sup>79</sup>. Moreover, reduction in LDL levels are suggested as a treatment strategy by the IDF<sup>80</sup>. This reflects the significance of LDL in metabolic syndrome. However, LDL alone might be an insufficient indicator and may thus be used along with other parameters in the assessment of MetS<sup>81</sup>. Therefore, we suggest that increased LDL may be one of the parameters to screen for MetS in children with T1DM. However, this implementation may require further assessment with large number of studies.

HDL is one of the parameters proposed by the IDF, WHO, and NCEP III to screen MetS. HDL is known to have a negative association with metabolic syndrome which was also reflected in our analysis. All datasets showed homogeneity for HDL; however, the cumulative effect size of HDL was moderate. Other than these markers, some of the inflammatory markers such as adiponectin and Leptin are under investigation for their association with increasing cardiometabolic risk in children with MetS<sup>66</sup>.

For IR, we came across only two studies where young patients with T1DM were classified based on presence or absence of IR. Diverse designs and varying parameters to test insulin resistance made the compilation of studies difficult. We came across a large number of non-invasive and invasive parameters used to assess IR in T1DM. Most of them are quantitative in nature (Supplementary Table 5). Routinely used quantitative measures include BMI and waist-to-height ratio. Initially, increased BMI was one of the components for IR detection. However, with recent observations of IR in lean T1DM children<sup>51</sup>, it has become evident that patients especially of Asian ethnicity may follow a 'thin fat' phenotype with low normal BMI, and high percent fat<sup>69</sup>. Therefore, waist-to-height ratio may be a better marker than BMI for IR detection. Increased dose of insulin is observed in patients with IR. Insulin dosage may vary depending on the meal type, physical activity etc. Thus, insulin dose may not represent the accurate status of IR in patients with T1DM. A qualitative marker-Acanthosis Nigricans (AN) may be observed as a result of abnormal proliferation of keratinocytes due to excessive binding of insulin to insulin like growth factor receptor rather than insulin receptor<sup>82</sup>. Also, acanthosis is observed to be associated with obesity more than insulin resistance. Therefore, a study to assess the specificity and sensitivity of acanthosis as a marker needs to be carried out.

Among the novel markers, breath test and cIMT offer least invasive methods for detection of IR. The breath test assesses the capacity to oxidize exogenous carbohydrates which directly correlate with eGDR and ISS significantly. This is presented by enriched C12/13 in expired breath<sup>73</sup>. This method being non-invasive can be more applicable to large paediatric cohorts. The cIMT (carotid intima media thickness), an early sign of atherosclerosis that correlate moderately with insulin sensitivity is not a direct measure for IR and the studies using this parameter are limited to associations for assessment of cardiovascular risk in patients. The test for cIMT is expensive and would be difficult to add in to a routine check-up.

Investigations of hormones that are directly or indirectly a part of the pathogenesis of insulin resistance might help if tested. Most of these hormones are novel and under investigation. These hormones actively participate in metabolic regulation and include adiponectin, leptin, fetuin A, Kisspeptin etc. Reduced adiponectin is observed in patients with T1DM<sup>53</sup>. Adiponectin which is suggested to be reduced in T1DM is involved in regulation of gluconeogenesis and is an insulin sensitizer (Table 3). Adiponectin showed a good discriminatory power for IR detection in non-diabetic adolescents<sup>83</sup>. However, this has not been assessed specifically in patients with T1DM. Another hormone leptin that is produced by white adipose tissues shows negative correlation with insulin sensitivity. Leptin is a hormone involved in energy balance and is involved in suppression of appetite, which in turn reduces the energy intake and also increases energy expenditure. The ratio of both these hormones has been evaluated in non-diabetic adolescents<sup>84</sup> however, this has not been investigated in case of children with T1DM. Fetuin A, a suggested marker for IR in non-diabetic adolescents is needed to be assessed in reference to HEC in T1DM<sup>85</sup>. Along with adiponectin, Kisspeptin was observed to be lower in patients with IR<sup>71</sup>. Kisspeptin is not very well studied; especially in case of T1DM, the role of Kisspeptin needs evaluation. An understanding of the pattern of these hormones with respect to IR provides a window for novel indices for the diagnosis of IR.

Other markers that are least understood and are under investigation include reduced D6D activity. Erythrocyte D6D activity has been suggested to be a strong marker of insulin resistance in T1DM<sup>64</sup>. D6D is a desaturase enzyme that introduces a double bond in a specific position of long chain fatty acids. Reduced activity of D6D can interfere with the fatty acid composition. The detailed explanation of this reduced activity is beyond the scope of our review. However, to consider D6D as an insulin resistance marker, more detailed studies are required.

## Strengths and limitations of the study:

To the best of our knowledge, this is the first systematic review and meta-analysis for assessment of surrogate markers for metabolic syndrome and a systematic review for insulin resistance in children with T1DM. However, for the insulin resistance, the studies are reported in different forms of indices which made it difficult for us to compile them for the assessment of IR markers. Also, this systematic review could not assess the effect of age and pubertal status on the accuracy of markers of metabolic syndrome and IR. The number of studies available for meta-analysis are very small hence, with increasing reports there are chances that the results may improve in future.

## **Conclusion:**

From the results it can be concluded that in the paediatric population with T1DM, markers of glycaemic control are not associated with MetS. Other than TG and HDL, LDL may also be considered in the diagnostic criteria for MetS. A combination of WC and TG may increase the efficacy of MetS diagnosis in paediatric patients with T1DM. Many novel markers currently under investigation for the diagnosis of IR need evaluation against HEC. These markers may be used in combination to increase the accuracy of IR diagnosis.

# **Declaration Section:**

**Author's Contribution**: SBK and VK performed the systematic literature search. SBK performed the statistical analysis. SBK and SPK wrote the manuscript. AK and SPK contributed to conceptual design of the study.

**Funding**: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Ethics declaration**: No ethical approval was needed as the data was collected from previous published studies in which the informed consent was obtained by primary investigators.

Competing interests: The authors declare no competing interest

**Acknowledgements**: SBK and VK thank SIU for research fellowships. SPK is a beneficiary of an extramural funding from SERB (SRG/2020/001414).

#### Reference:

- 1. Tuomilehto J. The emerging global epidemic of type 1 diabetes. *Curr Diab Rep.* 2013;13(6):795-804. doi:10.1007/s11892-013-0433-5
- 2. Id AG, Id ZJW, Id CR, et al. PLOS GLOBAL PUBLIC HEALTH Variation in the incidence of type 1 diabetes mellitus in children and adolescents by world region and country income group: A scoping review. Published online 2022:1-18. doi:10.1371/journal.pgph.0001099
- 3. Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. *Diabetes Res Clin Pract*. 2008;82(2):247-255. doi:10.1016/j.diabres.2008.07.022
- 4. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Fard HH, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. *Heal Promot Perspect*. 2020;10(2):98-115. doi:10.34172/hpp.2020.18
- 5. Tung JY ling, Kwan EY wai, But BW man, et al. Increasing incidence of type 1 diabetes among Hong Kong children and adolescents: The Hong Kong Childhood Diabetes Registry 2008 to 2017. *Pediatr Diabetes*. 2020;21(5):713-719. doi:10.1111/pedi.13016
- 6. Cherubini V, Rabbone I, Lombardo F, Mossetto G, Orsini Federici M, Nicolucci A. Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes in the real-life, post-Diabetes Control and Complications Trial setting: A systematic review. *Pediatr Diabetes*. 2019;20(6):678-692. doi:10.1111/pedi.12876
- 7. Vries L De, Lebenthal Y, Tenenbaum A, et al. Changes in weight and BMI following the diagnosis of type 1 diabetes in children and adolescents. Published online 2013. doi:10.1007/s00592-013-0524-4
- 8. Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2021;13(1):1-13. doi:10.1186/s13098-021-00641-8
- 9. Grabia M, Markiewicz-Żukowska R, Socha K. Prevalence of metabolic syndrome in children and adolescents with type 1 diabetes mellitus and possibilities of prevention and treatment: A systematic review. *Nutrients*. 2021;13(6):1-15. doi:10.3390/nu13061782
- 10. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome. *Circulation*. 2005;112(17):285-290. doi:10.1161/circulationaha.105.169405
- 11. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabet Med.* 1998;15(7):539-553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
- 12. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. *J Atheroscler Thromb*. 2005;12(6):295-300. doi:10.5551/jat.12.295
- 13. Soliman HM, Mosaad YO, Ibrahim A. The prevalence and the clinical profile of metabolic syndrome in children and adolescents with Type 1 diabetes. *Diabetes Metab Syndr Clin Res Rev.* 2019;13(3):1723-1726. doi:10.1016/j.dsx.2019.03.036
- 14. Köken ÖY, Kara C, Yılmaz GC, Aydın HM. Prevalence of obesity and metabolic syndrome in children with type 1 diabetes: A comparative assessment based on criteria established by the international diabetes federation, world health organisation and national cholesterol education program. *JCRPE J Clin Res Pediatr Endocrinol*. 2020;12(1):55-62. doi:10.4274/jcrpe.galenos.2019.2019.0048
- 15. Barros BSV, Santos DC, Melo LGN, et al. Genomic ancestry and metabolic syndrome in individuals with type 1 diabetes from an admixed population: a multicentre, cross-sectional study in Brazil. *Diabet Med*. 2021;38(2):1-9. doi:10.1111/dme.14400
- 16. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: What is "double diabetes" and what are the risks? *Diabetologia*. 2013;56(7):1462-1470. doi:10.1007/s00125-013-

2904-2

- 17. Kietsiriroje N, Pearson S, Campbell M, Ariëns RAS, Ajjan RA. Double diabetes: A distinct high-risk group? *Diabetes, Obes Metab.* 2019;21(12):2609-2618. doi:10.1111/dom.13848
- 18. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. *Diabetes*. 1982;31(9):795-801. doi:10.2337/diab.31.9.795
- 19. Minges KE, Whittemore R, Grey M. Overweight and obesity in youth with type 1 diabetes. *Annu Rev Nurs Res.* 2013;31:47-69. doi:10.1891/0739-6686.31.47
- 20. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes*. 2015;22(4):277-282. doi:10.1097/MED.00000000000170
- 21. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. *Diabetes Care*. 2011;34(SUPPL. 2). doi:10.2337/dc11-s213
- 22. Wolosowicz M, Lukaszuk B, Chabowski A. The causes of insulin resistance in type 1 diabetes mellitus: Is there a place for quaternary prevention? *Int J Environ Res Public Health*. 2020;17(22):1-13. doi:10.3390/ijerph17228651
- 23. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *Endocr Rev.* 2012;33(6):981-1030. doi:10.1210/er.2011-1034
- 24. Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. *Life Sci.* 2019;236:116940. doi:10.1016/j.lfs.2019.116940
- 25. Engin AB, Engin A. Obesity and Lipotoxicity. 2017;960. doi:10.1007/978-3-319-48382-5
- 26. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism*. 2016;65(8):1038-1048. doi:10.1016/j.metabol.2015.12.012
- 27. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ Linking NAFLD and Insulin Resistance. *Endocr Rev.* 2019;40(5):1367-1393. doi:10.1210/er.2019-00034
- 28. Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. *Diabetes Metab Syndr Clin Res Rev.* 2019;13(2):1449-1455. doi:10.1016/j.dsx.2019.02.023
- 29. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. *Am J Physiol Endocrinol Metab Gastrointest Physiol*. 1979;6(3). doi:10.1152/ajpendo.1979.237.3.e214
- 30. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. *Diabetes Care*. 2013;36(8):2280-2285. doi:10.2337/dc12-1693
- 31. Chillarón JJ, Goday A, Flores-Le-Roux JA, et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. *J Clin Endocrinol Metab*. 2009;94(9):3530-3534. doi:10.1210/jc.2009-0960
- 32. Nyström T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. *Diabetes, Obes Metab.* 2018;20(3):556-563. doi:10.1111/dom.13110
- 33. Bîcu ML, Bîcu D, Gârgavu S, et al. Estimated glucose disposal rate (eGDR) A marker for the assessment of insulin resistance in type 1 diabetes mellitus. *Rom J Diabetes, Nutr Metab Dis.* 2016;23(2):177-182. doi:10.1515/rjdnmd-2016-0021
- 34. Dabelea D, D'Agostino RB, Mason CC, et al. Development, validation and use of an insulin sensitivity score in youths with diabetes: The SEARCH for diabetes in youth study. *Diabetologia*. 2011;54(1):78-86. doi:10.1007/s00125-010-1911-9

- 35. Duca LM, Maahs DM, Schauer IE, et al. Development and validation of a method to estimate insulin sensitivity in patients with and without type 1 diabetes. *J Clin Endocrinol Metab*. 2016;101(2):686-695. doi:10.1210/jc.2015-3272
- 36. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "Double diabetes" in the diabetes control and complications trial. *Diabetes Care*. 2007;30(3):707-712. doi:10.2337/dc06-1982
- 37. Teixeira MM, De Fátima Haueisen Sander Diniz M, Reis JS, et al. Insulin resistance and associated factors in patients with Type 1 Diabetes. *Diabetol Metab Syndr*. 2014;6(1):1-10. doi:10.1186/1758-5996-6-131
- 38. Szadkowska A, Pietrzak I, Mianowska B, et al. Insulin sensitivity in Type 1 diabetic children and adolescents. *Diabet Med.* 2008;25(3):282-288. doi:10.1111/j.1464-5491.2007.02357.x
- 39. Snell-Bergeon JK, Maahs DM, Schauer IE, Bergman BC, Rewers M. A method for estimating insulin sensitivity in adults with type 1 diabetes. In: 70th Annual Meeting of the American Diabetes Association. Vol 25.; 2010:29.
- 40. Williams K V., Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? *Diabetes*. 2000;49(4):626-632. doi:10.2337/diabetes.49.4.626
- 41. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):1-10. doi:10.1186/s13643-016-0384-4
- 42. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol*. 2005;5:1-10. doi:10.1186/1471-2288-5-13
- 43. Package TM, Haenszel M-, Gpl L, Utf- BTE. Package 'metafor .' Published online 2022. doi:10.18637/jss.v036.i03>.License
- 44. Chang Y, Phillips MR, Guymer RH, et al. The 5 min meta-analysis: understanding how to read and interpret a forest plot. *Eye*. 2022;36(4):673-675. doi:10.1038/s41433-021-01867-6
- 45. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions*.; 2019. doi:10.1002/9781119536604
- 46. Cohen J. Cohen 1988. Published online 1988.
- 47. Sterne JAC, Harbord RM. Funnel Plots in Meta-analysis. *Stata J Promot Commun Stat Stata*. 2004;4(2):127-141. doi:10.1177/1536867x0400400204
- 48. Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: The SEARCH for diabetes in youth study. *Diabetes Care*. 2011;34(7):1628-1633. doi:10.2337/dc10-2324
- 49. Nishtala R, Kietsiriroje N, Karam M, Ajjan RA, Pearson S. Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study. *Diabetes Vasc Dis Res.* 2020;17(5). doi:10.1177/1479164120952321
- 50. Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. *J Clin Endocrinol Metab*. 2010;95(2):513-521. doi:10.1210/jc.2009-1756
- 51. Davis NL, Bursell JDH, Evans WD, Warner JT, Gregory JW. Body composition in children with type 1 diabetes in the first year after diagnosis: Relationship to glycaemic control and cardiovascular risk. *Arch Dis Child*. 2012;97(4):312-315. doi:10.1136/archdischild-2011-300626
- 52. Rathsman B, Rosfors S, Sjöholm Å, Nyström T. Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. *Cardiovasc Diabetol*. 2012;11:1-7. doi:10.1186/1475-2840-11-145
- 53. Safai N, Eising S, Hougaard DM, et al. Levels of adiponectin and leptin at onset of type 1 diabetes have changed over time in children and adolescents. *Acta Diabetol*. 2015;52(1):167-174. doi:10.1007/s00592-014-0630-y

- 54. Chan CL, Pyle L, Morehead R, Baumgartner A, Cree-Green M, Nadeau KJ. The role of glycemia in insulin resistance in youth with type 1 and type 2 diabetes. *Pediatr Diabetes*. 2017;18(6):470-477. doi:10.1111/pedi.12422
- 55. Cree-Green M, Stuppy JJ, Thurston J, et al. Youth with type 1 diabetes have adipose, hepatic, and peripheral insulin resistance. *J Clin Endocrinol Metab*. 2018;103(10):3647-3657. doi:10.1210/jc.2018-00433
- 56. Gourgari E, Stafford JM, D'Agostino R, et al. The association of low-density lipoprotein cholesterol with elevated arterial stiffness in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth study. *Pediatr Diabetes*. 2020;21(5):863-870. doi:10.1111/pedi.13021
- 57. Hamed N, Soliman A, De Sanctis V, et al. Clinical and metabolic characteristics of children with hybrid diabetes mellitus (Hd) compared to children with type 2 diabetes mellitus (t2dm): A preliminary comparative study. *Acta Biomed*. 2021;92(5):5-10. doi:10.23750/abm.v92i5.11598
- 58. Calcaterra V, De Silvestri A, Schneider L, et al. Acanthosis nigricans in children and adolescents with type 1 diabetes or obesity: The potential interplay role between insulin resistance and excess weight. *Children*. 2021;8(8):1-9. doi:10.3390/children8080710
- 59. Stone ML, Craig ME, Chan AK, Lee JW, Verge CF, Donaghue KC. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: A longitudinal study. *Diabetes Care*. 2006;29(9):2072-2077. doi:10.2337/dc06-0239
- 60. Lecaire TJ, Palta M. Longitudinal analysis of adiponectin through 20-year type 1 diabetes duration. *J Diabetes Res.* 2015;2015:18-20. doi:10.1155/2015/730407
- 61. Cedillo M, Libman IM, Arena VC, et al. Obesity, islet cell autoimmunity, and cardiovascular risk factors in youth at onset of type 1 autoimmune diabetes. *J Clin Endocrinol Metab*. 2015;100(1):E82-E86. doi:10.1210/jc.2014-2340
- 62. Şiraz ÜG, Doğan M, Hatipoğlu N, Muhtaroğlu S, Kurtoğlu S. Can fetuin-A be a marker for insulin resistance and poor glycemic control in children with type 1 diabetes mellitus? *JCRPE J Clin Res Pediatr Endocrinol*. 2017;9(4):293-299. doi:10.4274/jcrpe.4532
- 63. Sevaliev N, Strich D, Avnon-Ziv C, Levy-Khademi F. 10.1016/j.diabres.2020.108447. *J Pediatr Endocrinol Metab*. 2019;32(7):715-719. doi:10.1515/jpem-2018-0483
- 64. Morandi A, Piona C, Bonafini S, et al. Long chain fatty acids metabolism and cardiovascular risk factors in youth with type 1 diabetes. *Nutr Metab Cardiovasc Dis.* 2021;31(1):297-305. doi:10.1016/j.numecd.2020.08.023
- 65. Gomes MB, Conte D, Drummond KRG, et al. Overweight/obesity in adolescents with type 1 diabetes belonging to an admixed population. A Brazilian multicenter study. *Diabetol Metab Syndr*. 2022;14(1):1-10. doi:10.1186/s13098-021-00759-9
- 66. Khadilkar A. Adiponectin leptin ratio as a marker of cardio- metabolic risk in Indian children and youth with type 1 diabetes. *J Pediatr Endocrinol Metab*. Published online 2023:1-7. doi:10.1515/jpem-2023-0087
- 67. Valerio G, Iafusco D, Zucchini S, et al. Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. *Diabetes Res Clin Pract*. 2012;97(1):99-104. doi:10.1016/j.diabres.2012.01.022
- 68. Grabia M, Markiewicz-żukowska R, Socha K, et al. Prevalence of Metabolic Syndrome in Relation to Cardiovascular Biomarkers and Dietary Factors among Adolescents with Type 1 Diabetes Mellitus. *Nutrients*. 2022;14(12):1-18. doi:10.3390/nu14122435
- 69. Mazumder R, Sarkar D, Chowdhury BR, Chowdhury UR, Chowdhury S. Clinical assessment of obesity and insulin resistance in type 1 diabetes subjects seen at a center in Kolkata. *J Assoc Physicians India*. 2009;57(7):511-515.
- 70. Bjornstad P, Cree-Green M, Baumgartner A, et al. Leptin is associated with cardiopulmonary fitness

- independent of body-mass index and insulin sensitivity in adolescents with type 1 diabetes: a brief report from the EMERALD study. *J Diabetes Complications*. 2017;31(5):850-853. doi:10.1016/j.jdiacomp.2017.02.019
- 71. Calcaterra V, Nappi RE, Pelizzo G, et al. Insulin resistance and potential modulators of ovarian reserve in young reproductive-aged women with obesity and type 1 diabetes. *Gynecol Endocrinol*. 2021;37(9):823-830. doi:10.1080/09513590.2021.1940127
- 72. Ješić M, Ješić M, Sajić S, Bogićević D, Buljugić S, Maglajlić S. The effect of metabolic and hormonal parameters on microalbuminuria in adolescents with type 1 diabetes mellitus. *Srp Arh Celok Lek*. 2013;141(5-6):315-319. doi:10.2298/SARH1306315J
- 73. Marigliano M, Schutz Y, Piona C, et al. 13C/12C breath test ratio after the ingestion of a meal naturally enriched with (13C)carbohydrates is a surrogate marker of insulin resistance and insulin sensitivity in children and adolescents with Type 1 Diabetes. *Diabetes Res Clin Pract*. 2020;169:108447. doi:10.1016/j.diabres.2020.108447
- 74. Ibrahim MM, Elamragy AA, Girgis H, Nour MA. Cut off values of waist circumference & associated cardiovascular risk in egyptians. *BMC Cardiovasc Disord*. 2011;11(1):53. doi:10.1186/1471-2261-11-53
- 75. Ferreira-Hermosillo A, Ramírez-Rentería C, Mendoza-Zubieta V, Molina-Ayala MA. Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus. *Diabetol Metab Syndr*. 2014;6(1):1-7. doi:10.1186/1758-5996-6-32
- 76. Hirschler V, Aranda C, De Luján Calcagno M, Maccalini G, Jadzinsky M. Can waist circumference identify children with the metabolic syndrome? *Arch Pediatr Adolesc Med.* 2005;159(8):740-744. doi:10.1001/archpedi.159.8.740
- 77. de Cuevillas B, Alvarez-Alvarez I, Riezu-Boj JI, Navas-Carretero S, Martinez JA. The hypertriglyceridemic-waist phenotype as a valuable and integrative mirror of metabolic syndrome traits. *Sci Rep.* 2021;11(1):1-10. doi:10.1038/s41598-021-01343-x
- 78. Jung E, Kong SY, Ro YS, Ryu HH, Shin S Do. Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies. *Int J Environ Res Public Health*. 2022;19(14). doi:10.3390/ijerph19148272
- 79. Katsa ME, Ioannidis A, Sachlas A, Dimopoulos I, Chatzipanagiotou S, Gil APR. The roles of triglyceride/high-density lipoprotein cholesterol ratio and uric acid as predisposing factors for metabolic syndrome in healthy children. *Ann Pediatr Endocrinol Metab*. 2019;24(3):172-179. doi:10.6065/apem.2019.24.3.172
- 80. Powell EE, Jonsson JR, Clouston AD. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. *Dig Dis.* 2010;28(1):186-191. doi:10.1159/000282084
- 81. Paredes S, Fonseca L, Ribeiro L, Ramos H, Oliveira JC, Palma I. Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity. *Sci Rep.* 2019;9(1):1-7. doi:10.1038/s41598-019-48120-5
- 82. Phiske M. An approach to acanthosis nigricans. *Indian Dermatol Online J.* 2014;5(3):239. doi:10.4103/2229-5178.137765
- 83. de Cassia da Silva C, Zambon MP, Vasques ACJ, et al. Homeostatic model assessment of adiponectin (HOMA-Adiponectin) as a surrogate measure of insulin resistance in adolescents: Comparison with the hyperglycaemic clamp and homeostatic model assessment of insulin resistance. *PLoS One*. 2019;14(3):1-12. doi:10.1371/journal.pone.0214081
- 84. Agostinis-Sobrinho C, Vicente SE d. CF, Norkiene S, et al. Is the Leptin/Adiponectin Ratio a Better Diagnostic Biomarker for Insulin Resistance than Leptin or Adiponectin Alone in Adolescents? *Children*. 2022;9(8). doi:10.3390/children9081193
- 85. Shim YS, Kang MJ, Oh YJ, Baek JW, Yang S, Hwang IT. Fetuin-A as an alternative marker for insulin

- resistance and cardiovascular risk in prepubertal children. J Atheroscler Thromb. 2017;24(10):1031-1038. doi:10.5551/jat.38323
- 86. Zheng X, Huang B, Luo S, et al. A new model to estimate insulin resistance via clinical parameters in adults with type 1 diabetes. *Diabetes Metab Res Rev.* 2017;33(4). doi:10.1002/dmrr.2880
- 87. Cano A, Llauradó G, Albert L, et al. Utility of insulin resistance in estimating cardiovascular risk in subjects with type 1 diabetes according to the scores of the steno type 1 risk engine. *J Clin Med*. 2020;9(7):1-12. doi:10.3390/jcm9072192